Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2014198330) COMBINATION OF CD37 ANTIBODIES WITH CHLORAMBUCIL
Latest bibliographic data on file with the International Bureau   

Pub. No.: WO/2014/198330 International Application No.: PCT/EP2013/062365
Publication Date: 18.12.2014 International Filing Date: 14.06.2013
IPC:
C07K 16/28 (2006.01) ,A61K 31/195 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18
against material from animals or humans
28
against receptors, cell surface antigens or cell surface determinants
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
185
Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
19
Carboxylic acids, e.g. valproic acid
195
having an amino group
Applicants:
BOEHRINGER INGELHEIM INTERNATIONAL GMBH [DE/DE]; Binger Strasse 173 55216 Ingelheim Am Rhein, DE
Inventors:
HEIDER, Karl-Heinz; DE
BLUM, Petra; DE
Agent:
SIMON, Elke; Binger Strasse 173 55216 Ingelheim Am Rhein, DE
Priority Data:
Title (EN) COMBINATION OF CD37 ANTIBODIES WITH CHLORAMBUCIL
(FR) COMBINAISON D'ANTICORPS ANTI-CD37 ET DE CHLORAMBUCIL
Abstract:
(EN) The present invention relates to immunotherapies that are based on depletion of CD37- positive cells such as B-cells. The present invention provides methods for reduction of CD37-positive cells such as B-cells in an individual/ patient using a combination of CD37 antibody /antibodies and chlorambucil. The combination of CD37 antibodies and chlorambucilis shown to have a synergistic effect. The application further provides materials and methods for treatment of diseases involving aberrant B-cell activity.
(FR) Cette invention concerne des immunothérapies qui se basent sur l'appauvrissement des cellules positives à CD37 telles que les cellules B. Des méthodes de réduction des cellules positives à CD37 telles que les cellules B chez un individu/patient à l'aide d'une combinaison d'anticorps CD37 et de clorambucil sont en outre décrites, ladite combinaison s'avérant avoir un effet synergique. L'application concerne également des substances et des méthodes destinées à traiter des maladies impliquant une activité aberrante des cellules B.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)